Hepatitis C News and Research

Latest Hepatitis C News and Research

Idenix begins underwritten registered public offering of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has commenced an underwritten registered public offering of shares of its common stock. All of these shares are being sold by Idenix.

8 Apr 2011

CFFT, Vertex collaborate to develop new medicines for cystic fibrosis

Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics, Inc. today announced they will collaborate on the continued discovery and development of new medicines known as correctors that aim to treat the underlying cause of cystic fibrosis in people with the most common form of the disease.

8 Apr 2011

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment. Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

7 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

Scientists effectively combine two methods used as vehicles to carry DNA into cell nuclei

Scientists at Polytechnic Institute of New York University (NYU-Poly) and at the NYU College of Dentistry have discovered a biochemical version of a principle well known among confectioners. Call it the "peanut butter and chocolate" rule: Sometimes two things work better together than alone.

5 Apr 2011

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene,a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver over the weekend at the Internationales Congress Centrum in Berlin, Germany.

5 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry shows treatment with Risperdal Consta is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

5 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus in human hepatocytes.

4 Apr 2011

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

Bristol-Myers Squibb Company today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4, and complete early virologic response in genotypes 1 and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

4 Apr 2011

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.

4 Apr 2011

NAA joins with organizations worldwide to raise awareness about autism

The National Autism Association joins with organizations worldwide in recognizing April as Autism Awareness month. With one in 110 children now diagnosed with autism, and autism mortality rates doubling that of the general population, NAA is once again calling upon legislators and government health agencies to declare autism a national health emergency.

4 Apr 2011

New data: Quadruple therapy can effectively treat patients with HCV

Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.

2 Apr 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Idenix begins underwritten registered public offering of common stock

CFFT, Vertex collaborate to develop new medicines for cystic fibrosis

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

Scientists effectively combine two methods used as vehicles to carry DNA into cell nuclei

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Study demonstrates in vitro infection and HEV replication in human hepatocytes

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

NAA joins with organizations worldwide to raise awareness about autism

New data: Quadruple therapy can effectively treat patients with HCV

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Experts must monitor new antiviral compounds for HCV treatment

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in